Secretagogue Peptide

Tesamorlin

Size: 10MG

Select product size
Tesamorlin GREYLINE research vial
$139.982 vials · $69.99 per vial
Select quantity tier
2
VisaDiscoverMastercardAmerican ExpressApple PayBitcoin

For research use only. Not for human or veterinary use.

Product Description

Tesamorlin is presented as a stabilized 44-residue analog of human growth-hormone-releasing hormone (GHRH) that activates the GHRH receptor and stimulates pituitary growth-hormone release. An FDA-approved GHRH-analog acetate drug exists for reducing excess abdominal fat in adults with HIV-associated lipodystrophy; that narrow approval does not apply to general weight loss and does not establish equivalence of this research vial to an approved EGRIFTA formulation. The catalog spelling and 10 mg artwork support the named-ingredient entry, while lot composition and purity still require matching analytical documentation.

Certificate of Analysis

Lot-specific analytical results and downloadable documentation

Compound Information

Technical specifications

Molecular Profile

What is Tesamorlin?

Type
Stabilized GHRH analog peptide
CAS number
218949-48-5
Molecular weight
5136 g/mol
Amino acids
44-residue modified peptide
Molecular formula
C221H366N72O67S
PubChem: Tesamorlin-related compound record
Storage Requirements

Stability Information

Formulation-specific stability unknownKeep sealed and dryProtect from light
Lyophilized / unopenedNo product-specific shelf life supplied; follow a qualified laboratory SOP.
Reconstituted / in solutionNo authoritative hold time supplied; use a validated laboratory protocol.

FDA labeling contains storage instructions for specific EGRIFTA presentations, but the approved formulations differ and are not substitutable with an unlabeled 10 mg research formulation.

Sources & References

Peer-reviewed and authoritative records

Journal of Acquired Immune Deficiency Syndromes

Primary research

GHRH analog in HIV-associated abdominal fat accumulation: randomized trial and safety extension

Falutz J, Potvin D, Mamputu JC, et al.

View Source

ClinicalTrials.gov

Clinical trial registry

TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy (NCT00608023)

Theratechnologies

View Source

Important Research Notice

Not for human consumption. This product is sold exclusively for laboratory, analytical, and educational research purposes. It is not intended to diagnose, treat, cure, or prevent any disease.

Research information presented on this page is provided for educational reference and should not be interpreted as medical advice or as a product claim.

By purchasing this product, the customer confirms that it will be handled and used only by qualified individuals in accordance with all applicable laws and laboratory procedures.

Premium research peptides,
refined for modern researchers.

High purity. Verified quality. Trusted by researchers worldwide.

Shop Now